Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Otsuka Pharmaceutical Co., Ltd. |
---|---|
Information provided by: | Otsuka Pharmaceutical Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT00234078 |
The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.
Condition | Intervention | Phase |
---|---|---|
Dry Eye Syndromes |
Drug: OPC-12759 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Dose-Response Study of OPC-12759 Ophthalmic Suspension |
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 037E-04-002, JapicCTI-050040 |
Study First Received: | October 4, 2005 |
Last Updated: | September 27, 2007 |
ClinicalTrials.gov Identifier: | NCT00234078 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
OPC-12759 Dry eye syndromes |
Eye Diseases Lacrimal Apparatus Diseases Dry Eye Syndromes Rebamipide |
Antioxidants Pathologic Processes Disease Molecular Mechanisms of Pharmacological Action Therapeutic Uses Syndrome |
Physiological Effects of Drugs Anti-Ulcer Agents Gastrointestinal Agents Enzyme Inhibitors Protective Agents Pharmacologic Actions |